The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 17, 2019

Filed:

Feb. 09, 2016
Applicants:

Université DE Montréal, Montréal, Québec, CA;

Rsem, Limited Partnership, Montréal, Québec, CA;

Inventors:

Claude Perreault, Québec, CA;

Diana Paola Granados, Québec, CA;

Jean-Sébastien Delisle, Québec, CA;

Pierre Thibault, Québec, CA;

Sébastien Lemieux, Québec, CA;

Assignees:

UNIVERSITÉ DE MONTRÉAL, Montréal, CA;

RSEM, LIMITED PARTNERSHIP, Montréal, CA;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/74 (2006.01); A61K 35/13 (2015.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 1/04 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
C07K 14/70539 (2013.01); A61K 35/13 (2013.01); A61K 35/17 (2013.01); A61K 39/0011 (2013.01); C07K 1/047 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); A61K 39/00 (2013.01); A61K 2035/124 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5158 (2013.01); C07K 2319/02 (2013.01); G01N 2333/70539 (2013.01);
Abstract

Novel minor histocompatibility antigens (MiHAs) are described. These novel MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel MiHAs are also described. The present application also discloses the use of these novel MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.


Find Patent Forward Citations

Loading…